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Abstract
Background: People with chronic obstructive pulmonary disease (COPD) are at increased risk of depression and
anxiety, which greatly reduces their quality of life and is associated with worse outcomes; but these psychological
co-morbidities are under-recognised and undertreated in COPD patients. Pulmonary rehabilitation (PR) improves
mood for up to 6 months but health practitioners under-refer, and patients commonly fail to attend/complete PR.
Research suggests that complex non-pharmacological interventions, including both psychological and exercise
components, may reduce anxiety and depression in COPD.
We have developed a tailored, cognitive behavioural approach (CBA) intervention for patients with COPD and co-
morbid anxiety and/or depression (‘TANDEM’), which precedes and optimises the benefits of currently offered PR.
We hypothesise that such a psychological intervention, delivered by supervised, trained respiratory healthcare
professionals, will improve mood in patients with mild to moderate anxiety and/or depression and encourage
uptake and completion of PR.
Methods: We will conduct a multi-centre, pragmatic, randomised controlled trial of the TANDEM intervention
compared to usual care across the Midlands, London, the South East and Bristol, UK.
We will train healthcare professionals familiar with COPD to deliver the manualised, tailored, face-to-face, one-to-
one intervention weekly for 6–8 weeks.
We will recruit 430 participants from primary, community and secondary care with confirmed COPD and moderate
to very severe airflow limitation, who are eligible for assessment for PR, and who screen positive for symptoms of
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mild/moderate depression and/or anxiety using the Hospital Anxiety and Depression scale (HADS). Participants will
be randomised 1.25:1 (intervention: usual care).
The co-primary outcomes are the HADS anxiety and depression subscale scores at 6 months; participants will be
followed up to 12 months. Secondary outcomes include uptake and completion of PR and healthcare resource use.
There will be a parallel process evaluation and a health economic evaluation.
Discussion: The TANDEM intervention has the potential to optimise the unrealised synergy between a
psychological intervention and PR. The CBA sessions will precede PR and target individuals’ cognitions, behaviours
and symptoms associated with anxiety and depression to decrease psychological morbidity and increase effective
self-management amongst patients with COPD.
Trial registration: ISRCTN, ID: ISRCTN59537391. Registered on 20 March 2017. Protocol version 6.0, 22 April 2018.
Keywords: COPD, Co-morbidity, Depression, Anxiety, Cognitive behavioural approach, Pulmonary rehabilitation,
Complex intervention, Pragmatic randomised controlled trial, Clinical effectiveness, Health economic evaluation
Background
Chronic obstructive pulmonary disease (COPD) is an im-
portant public health problem associated with substantial
morbidity and mortality [1–3] and a global prevalence of
11.7% in adults aged over 30 years [1]. People with COPD
typically have multimorbidity, including psychological
problems [4–6], such as anxiety and depression, which
have a major influence on their quality of life and are asso-
ciated with worse survival [7, 8]. Anxiety is reported
across all ranges of COPD severity, with cited prevalence
ranging from 10 to 50% [9, 10]. The prevalence of depres-
sion (typically around 30% of all COPD patients [9, 11])
increases with the severity of COPD [12]. Psychological
problems are associated with lower levels of self-efficacy,
persistent smoking, impaired health status and worse
physical functioning [13, 14]. Additionally, people with
anxiety/depression experience more exacerbations, more
frequent and longer hospital admissions, and reduced
survival [10, 13, 15–17]. The individuals’ disease may also
affect the lives of their carers [18] creating a huge health-
care and economic burden [19, 20].
Despite effective interventions, co-morbid anxiety and
depression are under-recognised and undertreated [21, 22].
This may be due to a number of reasons. A dominant
medical culture results in very little attention to the
patient’s psychological well-being, in spite of its impact in
predicting disability and other outcomes [23]. Specific is-
sues include healthcare professionals feeling ill-equipped to
deal with emotional difficulties resulting from physical
illness, stigma relating to the use of psychiatric or
psychological services, and interpretation by patients that
referral for psychological therapy undermines the validity
of their symptoms. Pulmonary rehabilitation (PR), a well-
recognised, evidence-based intervention for the manage-
ment of COPD [24], reduces anxiety and depression [25]
at up to 6 months’ follow-up but practitioners under-refer,
and patients commonly fail to attend, or complete, their
PR course [26, 27].
Cognitive behavioural therapy (CBT) improves anx-
iety/depression and is now recommended in guidelines
for depression associated with long-term conditions [23],
although a large, observational study of the effectiveness
of routine, stepped-care psychological therapies for pa-
tients with long-term conditions in the UK found that
they did less well than people without long-term condi-
tions (controlling for co-variates) and that patients with
COPD were amongst those with poorest outcomes [28].
A systematic review of psychological interventions for
COPD identified four studies (total 193 participants) of
CBT in people with COPD compared to usual care or
education [29]. Although meta-analysis tended to favour
the intervention both for anxiety and depression, the re-
sults were not statistically significant and the authors
called for: ‘further research through well-designed and
appropriately powered studies before inclusion in COPD
guidelines or clinical care.... Furthermore, research is re-
quired to determine the most appropriate setting for the
delivery of effective psychological interventions to ensure
maximum benefit to patients with COPD.’
A 2013 systematic review of single or multi-component
intervention studies that included either psychological
and/or lifestyle interventions in patients with COPD
reported significant, moderate treatment effects on anxiety
and depression only in those interventions which also
included exercise components [30]. However, there was
great heterogeneity within the included studies, different
follow-up periods were combined, and only five of 29
included studies were directed at people identified as
anxious or depressed at baseline.
Building on this research we developed a tailored, psy-
chological cognitive behavioural approach (CBA) inter-
vention for patients with COPD and co-morbid anxiety
and/or depression (referred to as the TANDEM interven-
tion), which precedes, links into and optimises the benefits
of currently offered PR. We hypothesised that such a psy-
chological intervention, delivered by supervised, trained
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respiratory healthcare professionals who are very familiar
with COPD, would improve mood in people with mild to
moderate anxiety and depression.
This protocol describes a pragmatic, randomised con-
trolled trial (RCT) with a parallel health economic evalu-
ation which will assess whether delivery of the TANDEM
intervention prior to routine PR improves anxiety and/or
depression and is cost-effective in people with COPD with
moderate to very severe airflow limitation and mild to
moderate anxiety and/or depression. The RCT will also
assess whether the intervention encourages attendance
and completion of PR.
The protocol has been written following the Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) guidance [31] (see Additional file 1
populated SPIRIT Checklist).
Aims and objectives
The primary aim is to evaluate a tailored, psychological
cognitive behavioural approach (CBA) intervention (re-
ferred to as the TANDEM intervention), which precedes,
links into and optimises the benefits of currently offered
PR, with the aim of reducing mild/moderate anxiety
and/or depression symptoms in people with COPD and
moderate to very severe airflow limitation, as classified
in the COPD GOLD guidelines [32].
The specific objectives are:
1. To undertake a RCT of the TANDEM intervention
to examine the effectiveness of this intervention on
clinical outcomes compared to usual care (i.e. the
offer of PR alone)
2. To examine the effect of the TANDEM
intervention (which is directed at patients) on their
carers (where appropriate)
3. To determine the cost-effectiveness of the
TANDEM intervention from a National Health
Service (NHS) and personal social services
perspective
4. To conduct a process evaluation to inform the
implementation of the TANDEM intervention if the
trial is positive, or assist interpretation of findings if
it is negative
Trial design
This is a multi-centre, parallel-group, pragmatic, rando-
mised controlled, superiority trial including an internal
pilot. The unit of randomisation is the individual study
participant. We will also undertake a health economic
evaluation and a process evaluation. Throughout the
study and intervention design, delivery and assessment
we have considered the National Institute of Health
Behavioural Change Consortium’s treatment fidelity
framework [33, 34].
Public involvement, in the form of patients with
COPD and carers, are involved in the design and imple-
mentation of the trial to improve the relevance and
overall quality of the research [35].
Methods
Setting and participants
Recruitment sites include PR services across a wide
range of urban, suburban and rural areas: London, outer
London (Berkshire, Wessex), the Midlands (Birmingham,
Coventry, Leicester, Warwick) and Bristol, plus primary
care, community care and secondary care settings asso-
ciated with (i.e. able to refer patients to) these services,
(a full list is available from the authors).
Eligible participants are adults with a confirmed diag-
nosis of COPD with moderate to very severe airflow
limitation (Global Obstructive Lung Disease (GOLD)
criteria) who are eligible [32] to be assessed for PR at
their local service and, on screening, whose Hospital
Anxiety and Depression Scale (HADS) scores are
suggestive of mild to moderate: anxiety, depression or
both (i.e. depression or anxiety subscale scores in the
range ≥ 8 to ≤ 15 [36]). Patients who are receiving a psy-
chological intervention, or who have received this within
the preceding 6 months, are excluded but those taking
prescribed medication for anxiety or depression remain
eligible. Participants will also be invited to suggest a
carer we could approach to include in the study to
examine the effect of the patient-directed intervention
on their carers. A full list of inclusion and exclusion
criteria is provided in Table 1.
Intervention and comparator
Intervention group
The intervention is delivered on a one-to-one basis by
‘TANDEM Facilitators’ who are specially trained health-
care professionals experienced in working with people
with COPD (physiotherapists, nurses, occupational ther-
apists or psychologists). To avoid any risk of contamin-
ation by inadvertently exposing control group patients
to the TANDEM intervention content or ethos, mem-
bers of staff delivering PR in participating centres are
not eligible to deliver the TANDEM intervention.
We will describe the development of the intervention
and the facilitator training in detail elsewhere (in prepar-
ation). Briefly, the TANDEM intervention is a tailored,
manualised intervention which draws on: the principles
of cognitive behavioural therapy (CBT) recommended
for the treatment of anxiety and depression [23] in phy-
sical conditions including COPD [37–40]; our previous
work on The Lung Health Manual for anxiety in COPD
[41]; and self-regulation theory [42, 43]. Sessions are
reinforced with written and DVD-based materials
(TANDEM-specific hand-outs, leaflets and a DVD
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provided by the British Lung Foundation (see below)
and self-management leaflets adapted from the SPACE
manual [44], as indicated. Throughout the delivery of
the intervention there is an emphasis on the links
between symptoms (in particular breathlessness),
thoughts, feelings and behaviours. The intervention aims
to promote: techniques to manage breathlessness and to
increase physical activity; to reduce social isolation; and
to prepare for PR. Following the individual sessions, and
if they have met the local PR assessment criteria, the
participant has the opportunity to commence routine PR
at their local service.
The intervention is delivered face to face in the partici-
pant’s home, or at a nearby NHS venue of their choice,
weekly for 6 to 8 weeks, depending upon the severity of
their initial anxious or depressive symptoms, or the pres-
ence of symptoms of both conditions and the patient’s
individual progress. Sessions last for 40 to 60 min. On
completion, with the participant’s permission, a written
case summary is provided to their healthcare providers
to document progress and highlight any need for further
support. Between completing the TANDEM face-to-face
intervention and up to 2 weeks after completing PR,
facilitators also offer very brief (15 min or less), weekly
or less frequent (depending on participant preference),
CBA telephone support.
TANDEM Facilitators themselves receive regular tele-
phone supervision by an experienced clinical psycholo-
gist, or an experienced cognitive behavioural therapist,
trained in the supervision of TANDEM Facilitators. Fa-
cilitators receive telephone supervision at set times dur-
ing the delivery of the intervention for each patient
(typically, 15 min supervision after the second, third and
fifth weekly session for each participant receiving a 6-
week intervention.) Ad hoc telephone or email support
from supervising psychologists and the TANDEM chief
investigators is available throughout the study.
With participant permission, each face-to-face TAN-
DEM session will be digitally recorded on an encrypted
voice recorder. Trained health psychology coders will
rate up to two, randomly selected, complete sets of
intervention audio recordings per facilitator. The entire
face-to-face TANDEM intervention as delivered to the
participant will be rated for therapeutic competence and
adherence [45, 46]. To assess the fidelity of intervention
delivery psychologists experienced in health research will
design a checklist which incorporates the Cognitive First
Aid Rating Scale [45] and adherence to TANDEM con-
tent; specifically including both activities which should
happen repeatedly (such as feedback on home practice),
and session-specific activities (such as explaining inter-
vention aims in Session 1).
We will be alert to the possibility that, due to the pro-
gressive nature of COPD, there is potential for patient
participants to become increasingly distressed by their
situation and their physical condition. We do not en-
visage this happening but there is a small risk that some
participants may become much more anxious or
Table 1 Study inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Patients
• Adults with a confirmed diagnosis of COPD, post-bronchodilator FEV1/
FVC ratio < 70% on spirometry
• Moderate, severe or very severe COPD severity on spirometry,
FEV1 < 80% predicted
• Probable mild/moderate anxiety and/or depression as determined by
the HADS-A and/or HADS-D scores ≥ 8 to ≤ 15
• Eligible to attend assessment appointment at their local pulmonary
rehabilitation service at the time of randomisation i.e. 12 months have
elapsed since last undertook PR or participant has another indication for
PR referral (e.g. recent deterioration; recent hospitalisation with an acute
exacerbation of COPD) [31]
(Patients who have been offered PR previously but declined the offer or
did not complete PR will be included)
• Unable to give valid consent
• Patients with both HADS-A and HADS-D score < 8 (within normal range)
• Severe anxiety/depression suggested by HADS-A or HAD-D score > 15
• If a patient has an appointment to commence PR < 4 weeks after the
screening visit (because there is insufficient time to receive the TANDEM
CBA intervention prior to PR starting)
• Ineligible for PR at their local service at the time of randomisation (e.g.
< 12 months since undertaking a course of PR and no new clinical
indications [31]
• A co-morbidity so severe that it would prevent the patient from
engaging fully in the intervention and/or trial processes. (including:
severe uncontrolled psychological or psychiatric disorder; moderate/
severe cognitive impairment)
• In receipt of a psychological intervention primarily directed at helping
to manage anxiety or depression in the last 6 months (NB those taking
antidepressants/anxiolytics not excluded)
• Patients currently involved in another clinical trial related to COPD (to
avoid over-burdening participants)
• Insufficiently fluent in English to be able to complete the intervention
and/or questionnaires
Carers
• Identified by a participant as a ‘particular family caregiver or friend who
helps them’ whom they would be happy for us to invite to join the
study
• Unable to give valid consent
• Not sufficiently fluent in English to be able to complete
the questionnaires
Abbreviations: COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1 second, FVC forced vital capacity, HADS Hospital Anxiety and
Depression Scale (D Depression subscale, A Anxiety subscale) [34]; PR pulmonary rehabilitation
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depressed, or (very unlikely but more seriously) may ex-
press suicidal intent such that they are at risk of harm to
themselves or to others. Throughout the study, the CBA
facilitators will all receive ongoing supervision from a se-
nior clinical psychologist/nurse consultant (trained in
CBT) to help them identify and respond appropriately to
this possibility. The development of much worse depres-
sive or anxious symptoms, or suicidal ideation, would be
criteria for discontinuing the allocated (CBA) interven-
tion. These will be reported as adverse events which will
be recorded and reported in line with the Ethics
Committee’s and study sponsor’s requirements.
Control group
Participants in the control arm receive usual care and
will be referred to their local PR service in the usual
way. They will be offered the usual multidisciplinary PR
programme provided in their local area (including any
psychological treatment provided routinely in that ser-
vice). Because there is usually a delay between referral
and commencement of PR courses (in 2017 the median
waiting time was around 11 weeks [47]), and we are not
enrolling participants where the average waiting list for
PR is less than 4 weeks, control group participants will
attend PR at around the same time as the intervention
group.
In addition, all participants also receive a publicly
available British Lung Foundation (BLF) DVD: ‘Living
with COPD’/‘Stay Well Stay Active’ and a publicly avail-
able BLF COPD information and exercise and PR book-
let to ensure best usual care.
Outcomes
There is no agreed core outcome data set for trials in
COPD (http://www.comet-initiative.org). We selected
the HADS anxiety and depression subscales (HADS-A
and HADS-D, respectively) [36] as our co-primary out-
come measures since eligible participants may have
either (or both) conditions. A recent review of instru-
ments to screen for depression in COPD examined the
four most commonly used measures (including HADS)
and concluded that there was no evidence that any in-
strument was superior [11] but noted that HADS is the
only measure specifically validated in COPD patients
[48]. All outcome measures are collected at baseline, 6
and 12 months following randomisation. We elected to
measure primary outcomes at 6 months because we
hypothesised that our intervention would be effective
well within that timescale [30].
Secondary outcomes include: the Beck Anxiety Inven-
tory [49] and the Beck Depression Inventory II [50, 51];
respiratory-related quality of life using the St George’s
Respiratory Questionnaire [52]; the Brief Illness Percep-
tion Questionnaire [53]; social engagement (University
of Melbourne Health Education Impact Questionnaire
social engagement scale [54]); the EuroQol instrument
EQ-5D-5 L [55]; attendance at, and completion of, PR;
and smoking status. Social functioning will be measured
using an adapted version of the United Kingdom Time
Use Survey [56], which lists potential activities and asks
participants how many times they had engaged in the
activity in the week prior to assessment, how long was
spent doing the activity and whether this was done alone
or accompanied by with another person [57]. We will
also collect all healthcare resource use during the 12
months of follow-up. From participating carers we will
collect the Zarit Caregiver Burden Inventory [58] and
the Warwick Edinburgh Mental Well-Being Scale [59].
Table 2 shows all the study variables and data
collected from the study participants and carers. In
addition, data will be collected on adverse events and/or
serious adverse events related to study procedures.
Recruitment and study procedures
All study participants will provide written informed con-
sent and are aware that they can withdraw from the
study at any time. Potential participants will be recruited
through advertisements in secondary care and commu-
nity clinics or approached by clinical or clinical research
staff and asked if the study researcher may contact them
to discuss participation. We will also invite general prac-
tices proximate to selected participating PR centres to
screen their records for people who may be eligible and
to contact them by post. Potential study participants
who are interested will be assessed in the same manner
as those recruited from secondary or community care.
The study researcher will arrange spirometry and ad-
minister the HADS to confirm eligibility. Eligible partici-
pants will then be recruited to the study and baseline
data will be collected before randomisation to interven-
tion or control. Allocation will be concealed by use of a
remote, computer-generated randomisation service
based at the Pragmatic Clinical Trials Unit (PCTU)
(https://www.qmul.ac.uk/pctu/).
All patient and carer study participants will be
followed up in a location chosen by the participant
(home, GP practice, local hospital or community clinic)
at 6 and 12months by a study researcher. Baseline and
outcome data are collected as supervised, self-completed
questionnaires with provision for postal data collection if
requested by participants, and telephone follow-up for
primary outcomes only if participants fail to complete
questionnaires. With the exception of the visual
analogue scale of the EQ-5D-5 L (which has to be re-
corded on paper), participants will input questionnaire
data directly using OpenClinica software via a study tab-
let computer (with 3G/4G connection) unless they prefer
to use a paper version of the questionnaire. Researchers
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collecting data are blind to the allocation arm of parti-
cipants, who are asked not to disclose their treatment
allocation to researchers.
All study data will be uploaded onto a dedicated folder
on the secure virtualised environment at the Barts Cancer
Centre (BCC), Queen Mary University of London (trial
sponsor). This is where all data analysis of the PCTU trial
data is carried out. The BCC environment requires dual-
factor authentication to access the portal and the folders
where the data are stored are only accessible to the
appropriate members of the PCTU and the TANDEM
study team.
Figure 1 shows the study flow diagram. Figure 2 (SPIRIT
Figure) provides information on the study visits and the
activities/assessments at each visit. A process evaluation
and cost-effectiveness analysis will be performed.
A pilot RCT (n = 45) was completed in 2018. Data
from this will be incorporated as an internal pilot as no
significant changes were made to the intervention or to
study procedures.
Table 2 Study data collection
Abbreviation and footnotes: Sources: SP = study participant, PC = primary care medical records, NHD.D = NHS Digital, PR = pulmonary rehabilitation services, C =
carers, RT = research team, F = TANDEM facilitators, SD = study documentation. Outcome measures: HADS = Hospital Anxiety and Depression Scale (D =
depression sub-scale; A = anxiety subscale) [34]; mMRC = modified MRC breathlessness scale [61]; BAI = Beck Anxiety Inventory [47]; BDI II = Beck Depression
Inventory II[48]; SGRQ = St George’s Respiratory Questionnaire [50]; heiQ social eng = University of Melbourne Health Education Impact Questionnaire social
engagement scale [52]; IPQ-B = The brief illness perception questionnaire [51]; EQ-5D-5L = The EuroQol instrument [53]; ZBI = Zarit Caregiver Burden Inventory
[56]; WEMWBS= Warwick Edinburgh Mental Well-Being Scale [57]; n/a = not applicable.
*process evaluation interview data not included here.
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Sample size
Sample size calculations are based on the co-primary
outcomes: HADS-A (anxiety) and HADS-D (depression)
at 6 months. Based on a significance level of 2.5% and
90% power, recruiting 153 participants per arm (306 in
total) would allow us to detect a difference of 1.7 points
on the HADS-A subscale, and 1.5 points on the HADS-
D subscale (based on an SD of 4.2 for anxiety and 3.6
for depression [61]); these are equivalent to a standar-
dised mean difference of about 0.4.
In trials where there is clustering in one arm only,
power is maximised by using an unequal allocation ratio
favouring the group with clustering [60]. The exact allo-
cation ratio should be similar to the design effect used
to inflate the sample size. Due to the clustering effect by
Facilitator in the intervention arm, we increased the
sample size. Assuming an intra-class correlation coeffi-
cient between facilitators of 0.01 contributing to the
primary outcome, and 24 participants per therapist at
follow-up, leads to a design effect of 1.23, which requires
increasing the number of participants in the intervention
arm to 189 (342 overall). Assuming a study dropout rate
of 20%, we would require 428 participants overall. This
has been rounded up to 430. Using an allocation ratio of
1.25 vs. 1, this will lead to approximately 240 partici-
pants in the intervention arm and 190 in the control
arm.
Randomisation
Randomisation will be stratified by NHS Trust and mini-
misation used within each stratum with a random elem-
ent in order to minimise potential imbalances at
baseline for anxiety (HADS-A), depression (HADS-D),
breathlessness (mMRC – modified Medical Research
Council scale [62]) and smoking status.
Statistical analysis
Analyses will be by intention-to-treat (ITT): i.e. we will
analyse all participants, for whom an outcome is avail-
able, according to the treatment group to which they
were randomised. All analyses will account for clustering
by facilitator in the intervention arm, and each analysis
will present a treatment effect (difference in means for
continuous outcomes, odds ratios for binary outcomes)
with a 95% confidence interval and a two-sided p value.
Outcomes at 6 and 12months will be analysed using a
mixed-effects regression model that will account for cor-
relation within TANDEM Facilitators, and correlation
between outcomes at 6 and 12 months. Analyses will ad-
just for the outcome measured at baseline when pos-
sible. We will use a Hochberg procedure [63] to analyse
the two primary outcomes. Briefly, the Hochberg proced-
ure states that if either outcome has a p value < 0.025 then
that outcome is statistically significant; additionally, both
outcomes are significant if the p values are both < 0.05.
We will perform various sensitivity analyses. We will
assess the impact of any difference in time from baseline
to attending PR in intervention and control groups. Be-
cause our inclusion criteria states that participants must
have a score of ≥ 8 on either the HADS-A or HADS-D
subscale (but not necessarily both), some participants
will score < 8 on one of these subscales and have less
room for improvement during follow-up. We will assess
the impact of including such participants.
We will also perform sensitivity analyses to assess the
robustness of our results to various assumptions regard-
ing missing data, or participants lost to follow-up: for
this we will assess the feasibility of using a multiple
imputation approach (depending on the entity and the
structure of missingness). A detailed Statistical Analysis
Plan will be prepared by the PCTU statisticians and
signed off prior to unblinding.
Economic evaluation
The economic analysis will assess whether the addition
of a tailored psychological intervention, combined with
the availability of standard PR, is likely to be a cost-
effective use of resources. The economic evaluation will
take a NHS and Personal Social Services Perspective as
currently preferred by the National Institute for Health
and Care Excellence (NICE) [64]. TANDEM sessions
(both face to face and telephone contact) and TANDEM
Facilitator support will be recorded centrally. The eco-
nomic evaluation will be carried on an ITT basis (as per
the ‘Statistical analysis’).
Patient contact with PR will be extracted from clinical
records. Other community and hospital-based NHS and
social care service contacts will be recorded via patient
self-report using a version of the Adult Service Use
Schedule (AD-SUS) [65], supplemented where possible
with administrative data through primary care or NHS
Digital sources. Unit costs for costing patient contact
with the intervention will be developed using standard
health economic methodology [66]. Unit costs for PR
and other health and social care services will be ex-
tracted from published sources including the Unit Costs
of Health and Social Care [66] and national NHS refer-
ence costs [67].
Total health and social care costs will be compared be-
tween the groups using a regression model which controls
for baseline co-variates. Cost data are usually skewed and
so bootstrapped confidence intervals will be generated
around the cost difference. Incremental cost-effectiveness
will be evaluated based on the primary outcome measures
and on quality-adjusted life years gained (QALYs). The lat-
ter will be derived from the EQ-5D-5 L using area-under-
the-curve methods [68]. Point estimates of population
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Fig. 1 Study flow diagram
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mean cost and outcome differences between the groups will
be used to produce incremental cost-effectiveness ratios
(ICERs). Uncertainty around cost-effectiveness estimates on
account of trial sampling error will also be assessed using
cost-effectiveness acceptability curves and presentation of
the distribution of cost and outcome pairings within the
cost-effectiveness plane generated from bootstrap trial-data
simulations. Deterministic sensitivity analysis will also be
used to assess the sensitivity of cost-effectiveness conclu-
sions to changes in assumptions made regarding relevant
economic parameters. Any missing economic data will be
replaced using a multiple imputations approach (subject to
entity and structure of missingness).
The primary economic analysis will evaluate the within-
trial cost-effectiveness of the TANDEM intervention over
follow-up. However, given the possibility that the interven-
tion could improve engagement with PR over the longer
term, we will also explore the feasibility of adapting exist-
ing economic models of the impacts of COPD to provide
extrapolations of longer-term benefits to the NHS and pa-
tients of increased PR engagement beyond the trial period.
A detailed Health Economic Analysis Plan will be
prepared by the trial economists and signed off prior to
unblinding.
Process evaluation
A parallel-process evaluation [69] will be conducted. This
will assist the implementation of the intervention if the
trial is positive, or assist in the interpretation of findings if
the study is negative. The process evaluation will be in-
formed by Normalisation Process Theory [70, 71] and will
include: collection of process data (e.g. number and nature
of modules delivered to each intervention participant);
qualitative interviews with study participants and carers,
health care professional (HCP) facilitators delivering the
intervention and their clinical psychologist supervisors,
and a wide range of potential stakeholders including PR
teams, service managers, commissioners, general practi-
tioners and community psychology services; and assess-
ment of the fidelity of the delivery of the intervention
(described above). The full process evaluation will be de-
scribed in detail elsewhere (in preparation).
Discussion
The TANDEM intervention has the potential to opti-
mise the unrealised synergy between a psychological
intervention and PR. The CBA sessions will precede PR
and target individuals’ cognitions, behaviours and symp-
toms associated with anxiety and depression to decrease
psychological morbidity and increase effective self-
management amongst patients with moderate to severe
COPD. The hope is that this will also increase the likeli-
hood of attending and completing PR which in itself has
a positive effect on anxiety and depression, in addition
to benefits on quality of life and exercise tolerance. The
psychological and physical benefits of the TANDEM
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure: study visits, activity and assessments of patient and
carer participants
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individual sessions and PR are thus synergistic, though
even participants who do not engage with PR following
the CBA sessions should benefit.
The intervention has been designed so that realistically
it could be implemented across health services: screen-
ing people referred for PR for anxiety and depression
and intervening before they start PR; being delivered by
an existing group of health professionals who are famil-
iar with the management of COPD and the day-to-day
experiences of those living with advanced COPD; and
linking into, and optimising, routine PR.
Trial status
The trial is ongoing. Protocol version 6 dated 22 April
2018. The recruitment began on 14 June 2017 and is
likely to be completed by 31 March 2020.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-019-3800-y.
Additional file 1. Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 Checklist: recommended items to
address in a clinical trial protocol and related documents*.
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